SuperworthCastle Biosciences profit margin CSTL
Gross, operating and net profit as a share of revenue over the last twelve months, from 2018.
- Net margin, 12 months
- −5.4%
- Operating margin, 12 months
- −9.0%
- Net margin on a year earlier
- −2.7 pts
- Peer median
- 10.6%
Over the twelve months to Jun 30, 2026, Castle Biosciences kept −5.4% of its revenue as net profit, with an operating margin of −9.0% and a gross margin of 77.3%.
Five years earlier its net margin was −28.9%.
The median for 7 diagnostics and research stocks of a similar size is 10.6%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −7.0% | −12.4% | 79.4% |
| FY2024 | 5.5% | 2.6% | 81.9% |
| FY2023 | −26.1% | −30.9% | 79.5% |
| FY2022 | −49.0% | −53.2% | 76.6% |
| FY2021 | −33.3% | −42.6% | 83.2% |
| FY2020 | −16.4% | −10.4% | 84.5% |
| FY2019 | 10.2% | 14.1% | 85.9% |
| FY2018 | −27.9% | −16.8% | 76.8% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −5.4% | −2.7 pts | −9.0% | |
| Q1 FY26 | −3.8% | −2.3 pts | −9.8% | |
| Q4 FY25 | −7.0% | −12.5 pts | −12.4% | |
| Q3 FY25 | −3.6% | −5.5 pts | −10.2% | |
| Q2 FY25 | −2.7% | −1.7 pts | −6.7% | |
| Q1 FY25 | −1.5% | +10.8 pts | −4.0% | |
| Q4 FY24 | 5.5% | +31.6 pts | 2.6% | |
| Q3 FY24 | 1.9% | +41.3 pts | −0.3% | |
| Q2 FY24 | −1.1% | +52.0 pts | −5.5% | |
| Q1 FY24 | −12.3% | +34.8 pts | −16.7% | |
| Q4 FY23 | −26.1% | +22.8 pts | −30.9% | |
| Q3 FY23 | −39.3% | +3.5 pts | −44.3% |
Against its peers
Companies in Medical - Diagnostics & Research nearest Castle Biosciences' size, closest first, today.
| Company | Profit margin |
|---|---|
| CSTLCastle Biosciences | −5.4% |
| NRCNRC Health | 4.2% |
| CDNACareDx | 24.2% |
| VCYTVeracyte | 20.4% |
| BLLNBillionToOne | 9.5% |
| LNTHLantheus | 17.7% |
| CAICaris Life Sciences | 10.6% |
| BIOBio-Rad Laboratories | 8.6% |
| Peer median | 10.6% |
Where Castle Biosciences ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Castle Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.